Docket No. LFS-5015-USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Joel Racchini et al.

Serial No. : Unassigned

Art Unit: Unknown

Filed

: Herewith

Examiner: Unknown

For

: DEVICES, SYSTEMS AND METHODS FOR EXTRACTING BODILY

FLUID AND MONITORING AN ANALYTE THEREIN

EXPRESS MAIL LABEL NO.: EL 373 764 311 US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. \$1.56 and in accordance with 37 C.F.R. \$\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with \$1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application

(other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with \$1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ the fee of \$180.00 as set forth / in \$1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee.

Applicant(s) hereby petition(s) for consideration of this

Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of					
\$180.00 as set forth in \$1.17(p).					
$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $					
$\hfill \Box$ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:					
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.					
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.					
☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC \$371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).					
$\hfill\Box$. There are no listed references which are not in the English language.					
☐ The relevance of those listed references which are not in the English language is as follows: PCT Publication W001/47408 Al entitled "System for Improved Determination of					

the Level of Glucose in Interstitial Fluid", to Roche
Diagnostics, was published in the German language but contains
an English language abstract. The document is relevant to the
present application in that it is characteristic of the general
state of the art.

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/LFS-5015-USNP/MM.

Respectfully submitted,

Mayumi Maeda 8/20/03

Reg. No. 40,075 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (408) 956-4790

DATED: August 28, 2003

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

a collection of information unless it displays	a valid OMB control number.
Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Joel Racchini et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	LFS-5015-USNP

Examiner Initials	Cite No.1	U.S. Patent Document			-	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	
		US-2003/0018300	A1	Duchon et al.	01/23/2003	
		US-2003/0060784	A1	Hilgers et al.	03/27/2003	
		6,240,306	A1	Rohrschieb et al.	05/29/2001	
		6,332,871	A1	Douglas et al.	12/25/2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office ³	Number ⁴	KindCode ⁶	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	01/47408	A1	Roche Diagnostics Gmbh	07/05/2001		
		wo	02/49507	A1	Inverness Medical Ltd.	06/27/2002		
-						1		Τ

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

· Unique catation designation number - See attached kinds of U.S. Planto Documents. Effect Office that issued the document, by the he-lefter code (WIPO Standard ST.3). For Juspense patient document, be he location for he part of the right or he Emportor must proceed the serial number of the patient document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicate its to place a check mark here it English language Translation is attached.

Burdio Neuf Statement: This form is estimated to take 2.0 hours to complete. This will vary depending upon the needs of this Individual case. Any comments on the amount of time you are equipted to complete this from should be early to the Colle Information Officer. U. S. Fetterin and Todderwisk Office, WestIndgron, D.C 2023.1. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450